# Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow

> **NCT00172068** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 96 (actual)

## Conditions studied

- Primary Breast Cancer

## Interventions

- **DRUG:** Zoledronic acid + Calcium/Vitamin D

## Key facts

- **NCT ID:** NCT00172068
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-01
- **Primary completion:** 2008-11
- **Final completion:** —
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2009-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00172068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00172068, "Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00172068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*